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Abstract
Background: Few studies have investigated the impact of obesity on the response to tumor necrosis factor
inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA). The aim of our study was to investigate the impact
of different body mass index (BMI) categories on TNFi response in a large cohort of patients with axSpA.
Methods: Patients with axSpA within the Swiss Clinical Quality Management (SCQM) program were included in the
current study if they fulfilled the Assessment in Spondyloarthritis International Society (ASAS) criteria for axSpA,
started a first TNFi after recruitment, and had available BMI data as well as a baseline and follow-up visit at 1 year
(±6 months). Patients were categorized according to BMI: normal (BMI 18.5 to <25), overweight (BMI 25–30), and
obese (BMI >30). We evaluated the proportion of patients achieving the 40% improvement in ASAS criteria
(ASAS40), as well as Ankylosing Spondylitis Disease Activity Score (ASDAS) improvement and status scores at 1 year.
Patients having discontinued the TNFi were considered nonresponders. We controlled for age, sex, HLA-B27, axSpA
type, BASDAI, BASMI, elevated C-reactive protein (CRP), current smoking, enthesitis, physical exercise, and co-
medication with disease-modifying antirheumatic drugs, as well as with nonsteroidal anti-inflammatory drugs in
multiple adjusted logistic regression analyses.
Results: A total of 624 axSpA patients starting a first TNFi were considered in the current study (332 patients of
normal weight, 204 patients with overweight, and 88 obese patients). Obese individuals were older, had higher
BASDAI levels, and had a more important impairment of physical function in comparison to patients of normal
weight, while ASDAS and CRP levels were comparable between the three BMI groups. An ASAS40 response was
reached by 44%, 34%, and 29% of patients of normal weight, overweight, and obesity, respectively (overall p = 0.02).
Significantly lower odds ratios (ORs) for achieving ASAS40 response were found in adjusted analyses in obese
patients versus patients with normal BMI (OR 0.27, 95% confidence interval (CI) 0.09–0.70). The respective adjusted
ASAS40 OR in overweight versus normal weight patients was 0.62 (95% CI 0.24–1.14). Comparable results were
found for the other outcomes assessed.
Conclusions: Obesity is associated with significantly lower response rates to TNFi in patients with axSpA.
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Background
While the association of psoriasis and psoriatic arthritis
with obesity is established [1, 2], few studies have inves-
tigated the issue of obesity in patients with predomin-
antly axial involvement of spondyloarthritis (axSpA), and
particularly ankylosing spondylitis (AS). In a small study
of 46 patients with AS, an increased body mass index
(BMI) was associated with a greater disease activity and
functional limitation, as assessed by the Bath Ankylosing
Spondylitis Disease Activity and Functional Indices
(BASDAI and BASFI, respectively) [3]. These findings
were confirmed in a larger cohort of 461 axSpA patients
from the Netherlands [4].
Obese patients with psoriatic arthritis have been
shown to have a lower probability of obtaining min-
imal disease activity either in the absence of systemic
immunosuppressive treatment or upon treatment with
conventional or biologic disease-modifying antirheu-
matic drugs (DMARDs) [5, 6]. However, with regard
to AS patients, the impact of a high BMI on the
response to tumor necrosis factor inhibitors (TNFi)
has only been formally demonstrated for infliximab in
two retrospective studies [7, 8]. The aim of this study
was to investigate the impact of BMI on the response
to TNFi in a large cohort of patients with axSpA.
Methods
Study population
The Swiss Clinical Quality Management (SCQM)
rheumatologists established an ongoing cohort of pa-
tients diagnosed with axSpA in 2004 [9]. Assessments
at baseline and annual visits are performed according
to the recommendations of the Assessment of Spondy-
loArthritis International Society (ASAS) [10]. We in-
cluded patients in the current study if they fulfilled
the 2009 ASAS criteria for axSpA [11], if they had
started treatment with a first TNFi after recruitment,
and had baseline BMI data (visit allowed 0–3 months
before treatment start) and a follow-up visit at 1 year
(±6 months). Patients were categorized according to BMI
to the following groups: normal (BMI 18.5 to <25), over-
weight (BMI 25–30), and obese (BMI >30). As measured
height is influenced by kyphosis in advanced disease,
corrected height values were calculated by means of
geometry using the measurements of the occiput-to-
wall distance (see Additional file 1: Figure S1 and
Additional file 2: Figure S2).
We excluded patients with concurrent fibromyalgia
(as indicated by the treating rheumatologist in the co-
morbidity questionnaire; n = 25) and patients with a
BMI <18.5 (n = 18). The study was approved by the
Ethics Commission of the Canton of Zurich. All
patients provided written informed consent.
Response to treatment with a first TNF inhibitor
Response to anti-TNF treatment was assessed at 1 year
(±6 months). Patients having discontinued treatment
were considered as nonresponders [12]. The primary
outcome was the achievement of the 40% improvement
in ASAS criteria (ASAS40) [10]. The following add-
itional effectiveness measures were evaluated: the ASAS
criteria for partial remission (ASAS-PR), a 50% reduction
in the Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI-50), the proportion of patients achieving an An-
kylosing Spondylitis Disease Activity Score (ASDAS) <2.1
(reflecting moderate disease activity) or ASDAS <1.3
(corresponding to inactive disease), as well as a clinically
important improvement in ASDAS (change of ≥1.1 be-
tween baseline and follow-up) or a major improvement in
ASDAS (change of ≥2.0) [13]. Drug retention was assessed
as a further secondary outcome. Treatment courses
ongoing at the end of the study were censored at the last
visit registered in SCQM.
Statistical analysis
We compared baseline characteristics between different
BMI categories using the Fisher’s exact test for categorical
variables and the Mann-Whitney test for continuous vari-
ables. The significance of differences in crude response
rates at 1 year was assessed using the Fisher’s exact test.
Logistic regression analysis was used to estimate an ad-
justed ratio for ASAS40, ASAS-PR, BASDAI-50, ASDAS
clinically important or major improvement, and ASDAS
status scores <2.1 and <1.3 with adjustment for the follow-
ing parameters: age, gender, BASDAI, Bath Ankylosing
Spondylitis Mobility Index (BASMI), human leucocyte
antigen-B27 (HLA-B27), classification as nonradiographic
axSpA (nr-axSpA) vs. AS, elevated C-reactive protein
(CRP) status, physical exercise (yes/no), and current
smoking. We tested for interaction between the use of
infliximab and BMI categories. Drug maintenance was
evaluated with Kaplan-Meier plots and log-rank test, as
well as with multiple adjusted Cox proportional hazards
models to estimate a covariate-adjusted effect of BMI cat-
egories. The same covariates were used in this model as in
the response analysis (see above). R statistical software
was used for all analyses.
Results
A total of 624 patients had started a first TNFi after re-
cruitment into SCQM and fulfilled the inclusion criteria
(normal weight in 332 patients (53%), overweight in 204
patients (33%), and obesity in 88 patients (14%)). Base-
line characteristics of these patients are shown in Table 1.
Obese individuals were older, had higher BASDAI and
Maastricht Ankylosing Spondylitis Enthesitis Score
(MASES) levels, and a more important impairment of
physical function in comparison to patients of normal
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Table 1 Baseline characteristics at the start of first TNF inhibitor
Parameter n = 624 All Patients
n = 624
BMI category
Normal
n = 332
Overweight
n = 204
Obese
n = 88
BMI 624 25.4 (4.3) 22.3 (1.7) 27.0 (1.4)* 33.2 (3.2)* #
Male sex, % 624 62.2 55.7 73.5* 60.2
mNYc positive, % 437 73.9 73.1 75.2 74.1
Age, years 624 39.4 (11.6) 37.4 (11.3) 41.1 (11.7)* 43.2 (10.5)*
Symptom duration, years 619 13.0 (10.9) 12.2 (10.3) 13.6 (11.7) 14.5 (11.0)
HLA-B27 positive, % 571 78.1 80.5 77.2 70.9
BASDAI 549 5.5 (1.9) 5.3 (2.0) 5.6 (1.9) 6.1 (1.7)*
BASDAI Question 1 556 6.0 (2.3) 5.8 (2.3) 6.1 (2.2) 6.1 (2.0)
BASDAI Question 2 555 6.7 (2.3) 6.5 (2.4) 6.9 (2.2) 7.0 (2.1)
BASDAI Question 3 553 4.2 (3.0) 3.9 (3.0) 4.4 (3.0) 5.4 (2.8)*
BASDAI Question 4 556 5.2 (3.0) 5.1 (3.1) 5.2 (3.0) 5.8 (2.9)
BASDAI Question 5 554 6.1 (2.7) 5.9 (2.7) 6.3 (2.5) 6.6 (2.8)
BASDAI Question 6 554 4.9 (2.9) 4.9 (3.0) 4.8 (2.8) 5.3 (2.7)
Patient GA 552 6.4 (2.3) 6.2 (2.5) 6.6 (2.2) 6.6 (2.0)
Physician GA 600 4.9 (1.9) 4.9 (1.8) 4.9 (1.8) 5.2 (2.0)
ASDAS 517 3.5 (0.9) 3.4 (0.9) 3.5 (0.9) 3.7 (0.9)
CRP (mg/l) 584 15.1 (20.0) 15.3 (19.0) 14.0 (20.1) 16.9 (23.4)
Elevated CRP, % 581 53.4 54.8 50.0 55.4
BASFI 555 4.1 (2.5) 3.7 (2.4) 4.2 (2.4) 5.0 (2.6)*
BASMI, median (IQR) 540 2 (1–3) 2 (1–3) 2 (1–3) 2 (1–4)
EQ-5D 540 56.2 (20.9) 58.3 (20.7) 54.7 (20.8) 51.8 (21.2)*
Peripheral arthritis, % 606 34.2 32.9 35.9 34.9
Current enthesitis, % 605 71.9 69.1 71.7 82.8
Modified MASES, median (IQR) 599 2 (0–4) 1 (0–4) 2 (0–4) 4 (2–6)*#
Dactylitis ever, % 616 10.2 8.3 12.2 12.9
Uveitis ever, % 555 22.2 26.4 17.4 17.7
Psoriasis ever, % 478 12.3 13.0 10.6 14.3
Current smokers, % 527 36.4 39.2 31.2 38.2
Education, high, % 594 84.0 86.8 81.9 78.0
Exercise score†, median (IQR) 500 2.0 (0.0–4.0) 2.0 (0.0–4.0) 2.0 (0.0–3.0) 1.5 (0.0–3.0)
On NSAIDs, % 565 92.2 92.8 91.6 91.4
On DMARDs, % 624 12.5 11.2 13.2 15.9
On steroids, % 624 9.5 10.2 7.8 10.2
First TNFi used 624
Adalimumab, % 34.5 35.8 36.3 25.0
Certolizumab, % <0.1 0.3 1.0 0.0
Etanercept, % 26.7 24.4 28.9 28.4
Golimumab, % 16.9 17.2 14.2 21.6
Infliximab, % 21.9 22.3 19.6 25.0
Except where indicated otherwise, values are the mean (SD)
Significance levels of two-group comparisons are Bonferroni-corrected: *p< 0.015 compared with patients of normal weight; #p<0 .015 compared with patients who
are overweight
†Exercise score refers to the number of exercise sessions per week
Normal weight = BMI 18.5–25; overweight = BMI 25–30; obese = BMI >30
ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional
Index, BASMI Bath Ankylosing Spondylitis Metrology Index, BMI body mass index, CRP C-reactive peptide, DMARDs disease-modifying antirheumatic drugs, EQ-5D
EuroQol 5-domain, GA global assessment, HLA-B27 human leucocyte antigen-B27, IQR interquartile range, MASES Maastricht Ankylosing Spondylitis Enthesitis Score
(modification refers to the inclusion of the plantar fascia in the count), mNYc modified New York criteria, NSAIDs nonsteroidal anti-inflammatory drugs, TNFi tumor
necrosis factor inhibitor
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weight. There were no significant differences between
the BMI categories with regard to the ASDAS, as well as
regarding the proportion of patients with elevated CRP,
peripheral arthritis, and extraskeletal manifestations.
The use of individual biologics as a first TNFi was also
similarly distributed. The proportion of patients treated
with infliximab, which in contrast to the other anti-TNF
agents is dosed in a weight-dependent manner, was simi-
lar for the different BMI categories (22%, 20%, and 25%
for normal weight, overweight, and obesity, respectively;
overall p = 0.57). One year after TNFi initiation, mean
BASDAI (±SD) decreased from 5.3 ± 2.0 to 2.9 ± 2.2 in
normal weight patients, from 5.6 ± 1.9 to 3.2 ± 2.2 in
overweight patients, and from 6.1 ± 1.7 to 4.1 ± 2.4 in
obese patients. While the intensity of fatigue—as-
sessed by BASDAI question 1—was comparable be-
tween the three BMI categories at the start of TNFi
(overall p = 0.44; Table 1), it was significantly higher in
obese patients in comparison to patients of normal
weight and who were overweight at the 1-year follow-up
visit: mean levels (±SD) 5.0 ± 2.4 vs. 4.0 ± 2.7 vs. 4.1 ± 2.6,
respectively; overall p = 0.005. With regard to improve-
ment of enthesitis, median MASES (interquartile range
(IQR)) decreased from 1 (0–4) to 0 (0–2) in patients with
normal BMI, from 2 (0–4) to 0 (0–1) in overweight
patients, and from 4 (2–6) to 1 (0–3) in obese patients.
Data on disease activity at 1 year to assess at least one of
the predefined validated response criteria was available in
531 patients (85%). An ASAS40 response was reached by
44%, 34%, and 29% of patients of normal weight, over-
weight, and obesity, respectively (overall p = 0.02; Table 2).
Lower response rates for overweight and obese patients
were also demonstrated for the other outcomes assessed
(Table 2). Evaluation of crude ASAS40 responses following
stratification for treatment with infliximab versus treatment
with TNFi other than infliximab revealed similar response
rates in infliximab patients (42%, 36%, and 44% of patients
of normal weight, overweight and obesity, respectively;
overall p = 0.83), but not in patients treated with other
TNFi (Table 2). Direct comparisons between overweight
patients and normal weight patients, as well as obesity and
normal weight in unadjusted analyses are shown in
Additional file 3 (Table S1). Adjusted logistic regression
models were fitted in patients with available data regarding
known predictors of response to TNFi (n = 259 for the
ASAS40 response). A lower ASAS40 response was found
in adjusted analyses for overweight patients vs. normal BMI
patients as well as for obese patients vs. patients with nor-
mal BMI, reaching statistical significance only in the latter
(odds ratio (OR) 0.62, 95% confidence interval (CI) 0.24–
1.14 and OR 0.27, 95% CI 0.09–0.70, respectively; Model 1
in Table 3). Significantly lower improvement criteria and
status scores were also found in obese patients vs. patients
with normal BMI for all the other outcomes assessed
(Fig. 1a). The achievement of ASDAS improvement and
status scores were particularly impaired in obesity
(OR <0.15 for all four ASDAS outcomes). While lower
response rates were also found for overweight patients in
comparison to those with normal BMI, the differences did
not reach statistical significance (Fig. 1b).
To analyze whether missing covariate data affected
these results, unadjusted analyses were also performed
for the subpopulation of patients with complete covari-
ate values. Response rates in this subgroup of patients
were comparable to the outcomes of the whole popula-
tion (Additional file 4: Table S2).
In a sensitivity analysis of the adjusted ASAS40 re-
sponse, we included infliximab as a covariate as well as
interaction terms between infliximab administration and
the different BMI groups in the model in order to ac-
count for the fact that infliximab is dosed in a weight-
dependent manner (Model 2 in Table 3). Although no
Table 2 Crude response rates at 1 year of treatment with a first TNF inhibitor after stratification for different BMI categories
BMI category
Outcome n = 531 Normal
n = 282
Overweight
n = 178
Obese
n = 71
p
ASAS40 494 44% 34% 29% 0.02
ASAS40 TNFi other than INF 383 45% 34% 24% 0.008
ASAS40 TNFi: INF 111 42% 36% 44% 0.83
ASAS partial remission 531 39% 24% 17% <0.001
BASDAI-50 488 48% 40% 33% 0.06
ASDAS improvement ≥1.1 423 59% 46% 37% 0.003
ASDAS <2.1 468 56% 41% 25% <0.001
ASDAS improvement ≥2 423 25% 25% 13% 0.14
ASDAS <1.3 468 29% 15% 10% <0.001
Normal weight = BMI 18.5–25; overweight = BMI 25–30; obese = BMI >30
ASAS Assessment in SpondyloArthritis International Society, ASAS40 40% improvement according to ASAS, ASDAS Ankylosing Spondylitis Disease Activity Score,
BASDAI-50 50% improvement in Bath Ankylosing Spondylitis Disease Activity Index, BMI body mass index, INF infliximab, TNFi tumor necrosis factor inhibitor
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statistical significance could be demonstrated for these
interactions, the results suggest a trend for higher
ASAS40 responses in obese patients treated with inflixi-
mab versus obese patients treated with other anti-TNF
agents (OR 3.55, 95% CI 0.41–30.1; p = 0.24). This trend
was not found in overweight patients. However, in the
overall population, a trend for lower ASAS40 responses
was demonstrated in patients treated with infliximab
versus patients treated with other anti-TNF agents
(OR 0.66, 95% CI 0.26–1.65; p = 0.37).
With regard to drug maintenance, Kaplan-Meyer plots
demonstrated a comparable TNFi retention in the differ-
ent BMI groups (log-rank test p = 0.72; Fig. 2). The result
was confirmed in a multiple adjusted Cox proportional
hazards model (n = 356; Table 4). The hazard ratio (HR)
for discontinuing the first TNFi in obese patients in com-
parison to individuals with normal BMI was 1.01 (95% CI
0.63–1.65; p = 0.95). The respective HR for discontinu-
ation in overweight vs. normal weight patients was 0.98
(95% CI 0.79-1.38; p = 0.92).
Discussion
Up to 50% of patients with axSpA initiating a first TNFi in
the SCQM cohort presented with a BMI above the normal
range, and 14% were obese. Being overweight and particu-
larly obese was associated with an impaired response to
TNFi, as assessed by a multitude of validated outcomes.
Table 3 Multiple adjusted analysis of ASAS40 response in different BMI categories at 1 year of treatment with a first TNF inhibitor
Model 1 Model 2
Variable OR 95% CI p OR 95% CI p
Obese (ref: normal BMI) 0.27 0.09–0.70 0.01 0.18 0.05–0.59 0.008
Overweight (ref: normal BMI) 0.62 0.24–1.14 0.13 0.66 0.34–1.30 0.23
Age 1.01 0.99–1.04 0.32 1.01 0.98–1.04 0.36
HLA-B27 1.31 0.65–2.68 0.46 1.35 0.67–2.79 0.41
Male sex 2.41 1.28–4.66 0.007 2.57 1.35–5.01 0.005
nr-axSpA (ref: AS) 0.38 0.18–0.78 0.009 0.38 0.18–0.78 0.01
Current smoking yes vs. no 0.65 0.36–1.18 0.16 0.64 0.35–1.16 0.15
Exercise (ref: no exercise) 0.89 0.50–1.58 0.69 0.83 0.46–1.50 0.54
BASDAI 1.10 0.95–1.27 0.19 1.10 0.95–1.27 0.20
BASMI 0.76 0.63–0.90 0.002 0.75 0.63–0.89 0.002
Elevated CRP 1.69 0.94–3.08 0.08 1.65 0.91–3.03 0.10
Enthesitis 1.34 0.72; 2.52 0.36 1.29 0.69; 2.43 0.43
DMARDs 1.17 0.51; 2.71 0.71 1.14 0.48; 2.67 0.76
NSAIDs 1.21 0.39; 4.24 0.75 1.13 0.35; 4.07 0.84
Infliximab (ref: other TNFi) 0.66 0.26–1.65 0.37
Obese with infliximab (ref: other TNFi) 3.55 0.41–30.1 0.24
Overweight with infliximab (ref: other TNFi) 0.73 0.15–3.26 0.68
Analysis performed in 259 patients
AS Ankylosing Spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASMI Bath Ankylosing Spondylitis Mobility Index, BMI body mass index, CI
confidence interval, CRP C-reactive peptide, DMARDs disease-modifying antirheumatic drugs, HLA-B27 human leucocyte antigen-B27, nr-axSpA nonradiographic
axial spondyloarthritis. NSAIDs nonsteroidal anti-inflammatory drugs, OR odds ratio, ref reference, TNFi tumor necrosis factor inhibitor
0.0 0.5 1.0 1.5 2.0 2.5
Odds ratio and 95% confidence interval
BMI >30
BMI 25-30
a
b
Fig. 1 Impact of obesity (a) and overweight status (b) on different
outcomes after 1 year of treatment with a first TNFi in multivariable
analyses. Summarized results from different multivariable models
with the same covariates as used in Model 1 in Table 3. ASAS40 40%
improvement according to the Assessment in SpondyloArthritis
International Society criteria, ASAS-PR partial remission criteria
according to ASAS, ASDAS Ankylosing Spondylitis Disease Activity
Score, BASDAI-50 50% improvement in the Bath Ankylosing
Spondylitis Disease Activity Index, BMI body mass index, CII clinically
important improvement, MI major improvement
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While being overweight decreased the odds of achieving
an ASAS40 response upon TNF inhibition by about 30%,
the odds were decreased by 70% in obese patients.
Achievement of ASDAS improvement and status scores
was even more severely impaired in obese patients.
Importantly, BMI has been shown to not affect the deter-
mination of the ASDAS in a recent analysis of the SPACE
cohort [14]. A previous study had suggested that the nega-
tive impact of high BMI on treatment response might be
more important in patients treated with infliximab in
comparison to other anti-TNF drugs [8]. This finding is
intriguing as infliximab is the only anti-TNF agent admin-
istered in a weight-dependent manner. We hereby demon-
strate in a larger cohort of patients with axSpA that an
impaired response to TNFi is also found for the other
anti-TNF agents. The proportion of patients treated with
infliximab in our study was similar in all BMI categories,
indicating that rheumatologists in Switzerland do not
preferentially use infliximab for axSpA treatment in over-
weight and obese patients. We found a trend for a better
ASAS40 response in obese patients treated with infliximab
in comparison to treatment with other anti-TNF agents.
Our results suggest potential underdosing of subcutane-
ous TNFi in patients with obesity. An alternative, though
not mutually exclusive, hypothesis put forward to explain
the impaired treatment outcomes in obese patients with
inflammatory rheumatic diseases is the amplified produc-
tion of proinflammatory adipokines by fat tissue [15, 16].
Obese patients with psoriatic arthritis have indeed been
found to have a lower probability of achieving a sustained
minimal disease activity state independently of the use of
DMARDs and biologics [6].
We demonstrate that drug retention was similar irre-
spective of BMI category, indicating that in the ab-
sence of alternative treatment options some patients
remain on a particular anti-TNF agent despite an inad-
equate treatment response. This is in contrast to
current treatment recommendations, which stipulate
to consider continuing treatment only in patients with
an ASDAS and/or BASDAI improvement of ≥1.1 and ≥2,
respectively [17].
A positive effect of weight loss induced by hypocaloric
diet on TNFi response has been demonstrated in psori-
atic arthritis [18], indicating that obesity is a manageable
risk factor for the low performance of TNFi in inflam-
matory rheumatic diseases. Advice on the management
of obesity [19, 20] might thus not only reduce cardiovas-
cular risk but also improve therapeutic response. This
might be particularly important for TNFi usage which
has been shown to be associated with significant weight
gain in spondyloarthritis, mostly due to an increase in
android fat mass [21].
We utilized BMI as a proxy for overweight status
and obesity due to feasibility issues in this large co-
hort. This might be suboptimal, given the individual
variability in the relationship between BMI and body
fat [19]. Additional data using direct quantification
of fat mass in smaller cohorts of patients with
axSpA might help in elucidating the pathophysiology
of impaired treatment responses in patients with
high BMI.
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Fig. 2 Drug survival of the first TNFi, stratified by body mass index
(BMI) group
Table 4 Multiple adjusted Cox proportional hazards model for
analysis of drug discontinuation of a first TNF inhibitor in
different BMI categories
Variable HR 95% CI p
Obese (ref: normal BMI) 1.01 0.63–1.65 0.95
Overweight (ref: normal BMI) 0.98 0.79–1.38 0.92
Age 1.00 0.98–1.01 0.73
HLA-B27 positivity 0.86 0.60–1.25 0.43
Male sex 0.68 0.49–0.96 0.03
nr-axSpA (ref: AS) 1.47 1.01–2.14 0.04
Current smoking yes vs. no 0.92 0.66–1.28 0.61
Exercise yes vs. no 0.82 0.60–1.12 0.21
BASDAI 1.04 0.96–1.13 0.35
BASMI 1.07 0.97–1.18 0.17
Elevated CRP 0.71 0.51–0.98 0.04
Enthesitis 0.91 0.64–1.30 0.61
DMARDs 0.56 0.34–0.93 0.02
NSAIDs 1.00 0.55–1.83 0.99
Analysis performed in 343 patients
AS Ankylosing Spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity
Index, BASMI Bath Ankylosing Spondylitis Mobility Index, BMI body mass index,
CI confidence interval, CRP C-reactive peptide, DMARDs disease-modifying
antirheumatic drugs, HLA-B27 human leucocyte antigen-B27, HR hazard ratio,
nr-axSpA nonradiographic axial spondyloarthritis. NSAIDs nonsteroidal
anti-inflammatory drugs, ref reference, TNF tumor necrosis factor
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Some limitations are incurred given the observational
character of our real-life cohort and, in particular, missing
covariate data in the adjusted analyses. Crude response
rates in the subpopulation of patients with complete data
were comparable to the values in the unadjusted analyses
with all available patients.
Conclusion
In conclusion, obesity is associated with significantly
lower response rates to TNFi in patients with axSpA.
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B27: Human leucocyte antigen-B27; HR: Hazard ratio; MASES: Maastricht
Ankylosing Spondylitis Enthesitis Score; nr-axSpA: Nonradiographic axial
spondyloarthritis; OR: Odds ratio; SCQM: Swiss Clinical Quality Management;
TNFi: Tumor necrosis factor inhibitors
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